Under review

Rectal Artesunate

Under review

MMV Project Director: Pierre Hugo

Although the WHO Guidelines for the Treatment of Malaria include the use of rectal artesunate for pre-referral treatment for severe malaria, there is currently no WHO prequalified or stringent regulatory authority approved product of appropriate strength and presentation. This has hampered widespread availability and use of rectal artesunate, in programmes funded by international donors.

The project team is developing an rectal artesunate product that will be submitted to WHO Medicines Prequalification Programme in 2015. Read more information about this project in our Access areas of work.

Sulfadoxine-pyrimethamine + amodiaquine (SPAQ)

Under review

Project Leader: Aleksandra Misiorowska, MMV

Partner: Guilin Pharmaceutical Co. Ltd., China

Malaria is a major cause of childhood death. Children living in malaria-endemic regions during the rainy season, when mosquitoes are pervasive, are particularly vulnerable. Seasonal malaria chemoprevention (SMC) provides a degree of protection to vulnerable populations during the malaria season. It involves the intermittent administration of full treatment courses of an antimalarial, thereby maintaining therapeutic antimalarial drug concentrations in the blood throughout the period when the risk of malaria is greatest.1

In March 2012, WHO recommended SMC using a complete treatment of sulfadoxine-pyrimethamine and amodiaquine (SPAQ) once a month for 4 months during the malaria season for children aged between 3 and 59 months.2 In line with these recommendations MMV is working to enhance the reach of this treatment to populations that need it. Read more information about this project in our Access areas of work.

1. WHO website: Seasonal malaria chemoprevention

2. WHO website: Policy recommendation